Clinical trials: Primary Hypercholesterolaemia
Hypercholesterolemia, Atherosclerosis
Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)
The purpose of this study is to evaluate the effect of ezetimibe coadministered with simvastatin compared with simvastatin alone when administered for 12 weeks on endothelial function as assessed by brachial artery reactivity…
- Trial name
- NCT00651391
- Testing
- Ezetimibe + Simvastatin, Simvastatin
- Volunteers
- 28 people
- Sponsor
- Organon and Co
Primary Hypercholesterolemia
Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia
The purpose of this study is to evaluate efficacy and safety of HCP1306 in patients with primary hypercholesterolemia.
- Trial name
- NCT02205606
- Testing
- HGP0816 5mg, HGP0816 10mg, HGP0816 20mg
- Where
- South Korea
- Volunteers
- 412 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
The purpose of this study is to evaluate the efficacy and safety of SYH2053 monotherapy in patients with primary hypercholesterolemia (non-familial) or mixed dyslipidemia . This trial plans to enroll 760 Participants.
- Trial name
- NCT07421297
- Testing
- SYH2053 injection
- Where
- 2 sites in China
- Volunteers
- 760 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Hypercholesterolemia, Dyslipidemia
Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A
A Randomized, Double blind, Parallel, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A in Patient with primary Hypercholesterolemia or Mixed Dyslipidemia
- Trial name
- NCT05970679
- Testing
- Ezetimibe/Atorvastatin 10/5 mg, Atorvastatin 5mg, Ezetimibe 10mg
- Where
- South Korea
- Volunteers
- 252 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Hypercholesterolemia, Hyperlipidemia
A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)
This is a study to assess the safety, efficacy, and tolerability of MK0859 in patients with primary hypercholesterolemia (large amounts of cholesterol in the blood) or mixed hyperlipidemia (high levels of LDL cholesterol…
- Trial name
- NCT00565292
- Testing
- MK0859
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia and Mixed Hyperlipidemia
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
The purpose of this study is to compare the effectiveness, safety of SYH2053 in Participants with primary hypercholesterolemia or mixed dyslipidemia. A total of 156 Participants were actually enrolled
- Trial name
- NCT07421232
- Testing
- Inclisiran (Leqvio®) 300mg
- Where
- China
- Volunteers
- 156 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Hypercholesterolemia, Mixed Hyperlipemia
MK0859 Dose-Ranging Study (0859-003)
To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.
- Trial name
- NCT00325455
- Testing
- MK0859
- Volunteers
- 500 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Hypercholesterolemia or Mixed Hyperlipidemia
QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia
This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 monotherapy in adults with non-familial primary hypercholesterolemia or mixed dyslipidemia who are not receiving lipid-lowering therapy.
- Trial name
- NCT07444086
- Testing
- QLC7401
- Volunteers
- 510 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Primary Hypercholesterolemia, Mixed Dyslipidemia
A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
This study is to generate post-marketing safety and effectiveness data of inclisiran sodium in Indian patients as per approved indication i.e., primary hypercholesterolemia (heterozygous familial and non-familial) or mixed…
- Trial name
- NCT06386419
- Testing
- inclisiran
- Where
- 9 sites in India
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension, Primary Hypercholesterolemia
To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.
This prospective study aims to observe changes in renal function and related parameters in patients with essential hypertension and primary hypercholesterolemia receiving either the combination of fimasartan and atorvastatin or…
- Trial name
- NCT07685054
- Volunteers
- 12,700 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Primary Hypercholesterolemia, Mixed Dyslipidemia
A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib
The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin/Ezetimibe under the real-world condition
- Trial name
- NCT06314919
- Where
- South Korea
- Volunteers
- 8,606 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypercholesterolemia
Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)
The overall objective is to evaluate the efficacy and safety of ezetimibe (SCH 058235/MK-0653) 10 mg administered daily in conjunction with atorvastatin in participants with Heterozygous Familial Hypercholesterolemia (HeFH) or in…
- Trial name
- NCT03867318
- Testing
- Atorvastatin, Ezetimibe
- Volunteers
- 621 people
- Sponsor
- Organon and Co
Primary Hypercholesterolemia, Dyslipidemia
A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets…
- Trial name
- NCT01294683
- Testing
- Simvastatin, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), Extended Release (ER) niacin/laropiprant (N/LRPT)
- Volunteers
- 977 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Dyslipidemia
Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
This study is a long-term follow-up protocol for patients who participated in study NK-104-3.01EU or study NK-104-3.02EU.
- Trial name
- NCT00325780
- Testing
- Pitavastatin
- Where
- 186 sites in Denmark, Finland and 11 more
- Volunteers
- 1,355 people
- Sponsor
- Kowa Research Europe
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia
- Trial name
- NCT06165250
- Testing
- BR1018A, BR1018A-1, BR1018B
- Where
- 2 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Myalgia, Hypercholesterolemia
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
The purpose of this study is to assess the incidence of statin-associated myalgia (SAM) with treatment with PPD10558 versus atorvastatin in patients previously intolerant to statins.
- Conditions
- Myalgia, Hypercholesterolemia, Hyperlipidemia
- Trial name
- NCT01279590
- Testing
- PPD10558, Atorvastatin
- Where
- 67 sites in United States
- Volunteers
- 282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A
The purpose of this study is to evaluate the efficacy and safety of AD-221 and AD-221A
- Trial name
- NCT05131997
- Testing
- AD-221, AD-221A, AD-221B
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Addpharma Inc.
Atherosclerosis, Hypercholesterolemia
Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)
This study will assess whether the daily co-administration of ezetimibe 10 mg with ongoing treatment of simvastatin 20 mg will be more effective than treatment with simvastatin 20 mg alone in further reducing LDL-C concentrations.
- Conditions
- Atherosclerosis, Hypercholesterolemia, Coronary Heart Disease
- Trial name
- NCT00651274
- Testing
- Ezetimibe
- Volunteers
- 144 people
- Sponsor
- Organon and Co
Hyperlipidemia
Clinical Trial to Evaluate the Efficacy and Safety of CKD-391
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Factorial Design, Phase III Clinical Trial.
- Trial name
- NCT02451098
- Testing
- Atorvastatin10mg, Ezetimibe10mg, Atorvastatin20mg, Ezetimibe10mg, Atorvastatin40mg, Ezetimibe10mg
- Where
- South Korea
- Volunteers
- 385 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Mixed Dyslipidemia, Hypercholesterolemia
Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia
The purpose of the study is to evaluate the safety and tolerability of fluvastatin 80 mg in a Chinese population. This study is not recruiting patients in the US.
- Trial name
- NCT00136799
- Testing
- Fluvastatin
- Where
- China
- Volunteers
- 325 people
- Sponsor
- Novartis